Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L C Pronk

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Rheumatology International|January 1, 1991
Pulmonary hypertension in connective tissue disease. Report of three cases and review of the literatureL C Pronk, A J Swaak
Cancer Treatment Reviews|September 1, 1995
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effectsL C Pronk, G Stoter, J Verweij
Drugs|January 1, 1996
Emerging drug treatments for solid tumoursJ H Schellens, L C Pronk, J Verweij
Journal of Cancer Research and Clinical Oncology|January 1, 1997
The correlation of CA15.3 and TPS with tumor course in patients with metastatic breast cancerL C Pronk, G Stoter, W L van Putten, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholineL C Pronk, A S Planting, R Oosterom, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative studyL C Pronk, W L van Putten, V van Beurden, et al.
Anti-Cancer Drugs|December 5, 1998
Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxelL C Pronk, P H Hilkens, M J van den Bent, et al.
British Journal of Cancer|January 1, 1997
Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatinP H Hilkens, L C Pronk, J Verweij, et al.
British Journal of Cancer|July 7, 2000
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumoursL C Pronk, P Vasey, A Sparreboom, et al.
Seminars in Oncology|April 16, 1998
Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I studyL C Pronk, D Schrijvers, J H Schellens, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Rheumatology International|January 1, 1991
Pulmonary hypertension in connective tissue disease. Report of three cases and review of the literatureL C Pronk, A J Swaak
Cancer Treatment Reviews|September 1, 1995
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effectsL C Pronk, G Stoter, J Verweij
Drugs|January 1, 1996
Emerging drug treatments for solid tumoursJ H Schellens, L C Pronk, J Verweij
Journal of Cancer Research and Clinical Oncology|January 1, 1997
The correlation of CA15.3 and TPS with tumor course in patients with metastatic breast cancerL C Pronk, G Stoter, W L van Putten, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholineL C Pronk, A S Planting, R Oosterom, et al.
Cancer Chemotherapy and Pharmacology|January 29, 1999
The venotonic drug hydroxyethylrutosiden does not prevent or reduce docetaxel-induced fluid retention: results of a comparative studyL C Pronk, W L van Putten, V van Beurden, et al.
Anti-Cancer Drugs|December 5, 1998
Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxelL C Pronk, P H Hilkens, M J van den Bent, et al.
British Journal of Cancer|January 1, 1997
Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatinP H Hilkens, L C Pronk, J Verweij, et al.
British Journal of Cancer|July 7, 2000
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumoursL C Pronk, P Vasey, A Sparreboom, et al.
Seminars in Oncology|April 16, 1998
Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I studyL C Pronk, D Schrijvers, J H Schellens, et al.
Pageof 2